Specific Targeting of Lipid Nanoparticles
Achieve targeted extrahepatic delivery using NanoPilot™ technology.
TechnologyContact usOur Mission
Revolutionising drug delivery
Specific targeting of lipid Nanoparticles
At Hone Bio, we are revolutionising lipid nanoparticle drug delivery through our NanoPilot targeting technology.
Lipid nanoparticles (LNPs) are drug delivery vehicles that protect and transport their therapeutic payload throughout the body. While they have shown immense potential, particularly in delivering mRNA vaccines, they face a significant challenge: most LNPs accumulate in the liver. This limits their effectiveness for targeting other extrahepatic organs and tissues, and risks off-target effects.
Additional technology is required to ensure safe, precise delivery.
Our innovative platform technology addresses this limitation head-on. We are developing our NanoPilot constructs to engineer LNPs that will:
- Target specific cell types with unprecedented precision
- Minimise off-target effects, enhancing both safety and efficacy
- Unlock new possibilities for treating diseases beyond the liver
By improving the targeting capabilities of LNPs, we aim to provide advances in drug delivery, and enable new therapeutic possibilities.
Our platform technology
Unlock the full potential of targeted lipid nanoparticles with NanoPilot
NanoPilot
Powerful targeting whilst blocking non-specific uptake
Conventional LNP therapeutics accumulate in the liver, significantly limiting the potential of LNPs to deliver powerful nucleic-acid payloads, such as DNA or mRNA, for in vivo genetic engineering.
Existing targeting strategies either use binders that do not address off-target endocytosis, or develop LNP formulations that bias delivery towards certain tissues but without the ability to target specific cells.
NanoPilot uses a proprietary dual targeting mechanism that actively blocks non-specific LNP uptake, whilst simultaneously providing highly specific targeting. Its modular design enables rapid, high-throughput prototyping for producing bespoke NanoPilot constructs for myriad applications.
The LNP coating process is simple, rapid, and requires no special equipment, with targeted LNPs achievable in less than an hour. NanoPilot is also compatible with most LNP formulations.
Applications
Targeted delivery to address therapeutic challenges
NanoPilot is the solution for applications where maximum target specificity is required. Our proprietary targeting technology is designed to enhance the specificity of LNP delivery, and we are exploring their potential across multiple therapeutic modalities, including cell and gene therapies, vaccines for infectious diseases, cancer vaccines, and autoimmune conditions.
NanoPilot's targeting is driven by antibodies, and its modular design enables rapid prototyping towards novel applications. New constructs can be tailor-made for indications by simply identifying a suitable antibody for the target cells.
If you are interested in leveraging NanoPilot's cell-specific targeting for your use-case, get in touch.
About us
Hone Bio is a VC-backed pre-clinical biotech company based in Bristol, United Kingdom, developing LNP targeting technologies for enhanced drug delivery.
We are proudly part of the Science Creates ecosystem.
Connect with us on LinkedIn.
FAQs
Why is targeting LNPs important?
By targeting your LNP specifically to the target cell, more drug would be delivered to its site of action for a given dose, which would lead to enhanced drug potency and reduced off-target toxicity.
How does NanoPilot bind to LNPs?
NanoPilot binds to the LNP surface via a proprietary mechanism that provides tight binding whilst blocking off-target endocytosis. The coating procedure is performed on pre-formulated LNPs, and is simple and rapid.
Why use NanoPilot instead of chemistry to coat LNPs with antibodies?
In addition to being simple and rapid to apply, NanoPilot actively blocks off-target transfection in addition to providing targeting, which is unique to the technology.
Is NanoPilot compatible with all LNP formulations?
NanoPilot is compatible with all common LNP formulations. Contact us if you would like to ask about compatibility with a specific LNP formulation.
Can NanoPilot be tailored for different applications?
The modular design of NanoPilot makes it simple to change the targeting domain to suit a given application. The only prerequisite is that an antibody suitable for targeting the cell is known.
If you would like to explore the use of NanoPilot for your use case, contact us to find out how we can help.
Can NanoPilot be licensed for research use?
Yes. Please get in touch via the contact form to discuss licensing.
Is NanoPilot available for therapeutic use?
Hone Bio's proprietary NanoPilot targeting technology is currently for research purposes only and has not been approved for clinical use or therapeutic applications by regulatory authorities.
Contact us
We want to hear from you
If you want to learn more about our technology, are interested in licensing, or have any other enquiries, contact us using the form linked below.
Click here to get in touch